Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short-term Investments (2016 - 2025)

IGC Pharma has reported Short-term Investments over the past 11 years, most recently at $25000.0 for Q3 2025.

  • Quarterly Short-term Investments changed N/A to $25000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $154000.0 for FY2023, N/A changed from the prior year.
  • Short-term Investments was $25000.0 for Q3 2025 at IGC Pharma, down from $98000.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $227000.0 in Q2 2023 and troughed at $25000.0 in Q3 2025.
  • The 4-year median for Short-term Investments is $98000.0 (2023), against an average of $123571.4.
  • The largest YoY upside for Short-term Investments was 49.22% in 2023 against a maximum downside of 49.22% in 2023.
  • A 4-year view of Short-term Investments shows it stood at $80000.0 in 2021, then increased by 10.0% to $88000.0 in 2022, then grew by 11.36% to $98000.0 in 2023, then tumbled by 74.49% to $25000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Short-term Investments are $25000.0 (Q3 2025), $98000.0 (Q3 2023), and $227000.0 (Q2 2023).